Luteinizing Hormone Releasing Hormone (LHRH) Agonists Market Analysis

  • Report ID: 3037
  • Published Date: Sep 23, 2024
  • Report Format: PDF, PPT

Luteinizing Hormone Releasing Hormone (LHRH) Agonists Market Analysis

The luteinizing hormone releasing hormone (lhrh) agonists market is segmented by drug type into Eligard, Zoladex, Lupron, Vantas and others. Amongst these segments, the Eligard segment is projected to grab a significant market share in the year 2021. The growth of the segment can be attributed to the rising usage of the drug for the treatment of prostate cancer.

Our in-depth analysis of the global market includes the following segments:

           By Drug Type

  • Eligard
  • Zoladex
  • Lupron
  • Vantas
  • Others

             By Patient Type

  • Males
  • Females

By End Users

  • Hospitals
  • Specialty Clinics
  • Others
 

 

 

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3037
  • Published Date: Sep 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The high effectiveness of LHRH agonists in prostate cancer is one of the major factors driving the market growth.

The market is anticipated to attain a significant CAGR over the forecast period, i.e., 2021-2029.

The concern for the side effects associated with the hormone is one of the major factors estimated to act as barriers to the growth of the market.

The major companies in the market are F. Hoffmann-La Roche Ltd, Novartis Pharmaceuticals Corporation, Siemens Healthcare Private Limited, Pfizer Inc., Clovis Oncology, Genomic Health, Inc., Myriad Genetics, Inc., and others.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample